Trials / Completed
CompletedNCT06210919
Safety and Tolerability of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars
A Phase 1, Single-Center, Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Single Dose of TRTP-101 in Adults With Atrophic Scars
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- CellinCells · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this clinical trial was to evaluate the safety and tolerability for 12 weeks after one dose of TRTP-101 in adults with atrophic scars.
Detailed description
A phase 1 clinical trial to evaluate dose-limiting toxicity by administering a singe dose of TRTP-101 to each of the four sites of atrophic scar.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | TRTP-101 | Intradermal injection of the each of four sites |
Timeline
- Start date
- 2023-12-06
- Primary completion
- 2024-12-10
- Completion
- 2025-03-28
- First posted
- 2024-01-18
- Last updated
- 2025-08-12
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06210919. Inclusion in this directory is not an endorsement.